Free Trial

Galmed Pharmaceuticals (GLMD) Competitors

Galmed Pharmaceuticals logo
$1.38 -0.01 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$1.31 -0.07 (-5.00%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLMD vs. BFRI, DWTX, PRTG, SNGX, NLSP, RNAZ, CSCI, SNOA, TLPH, and ADIL

Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Biofrontera (BFRI), Dogwood Therapeutics (DWTX), Portage Biotech (PRTG), Soligenix (SNGX), NLS Pharmaceutics (NLSP), TransCode Therapeutics (RNAZ), COSCIENS Biopharma (CSCI), Sonoma Pharmaceuticals (SNOA), Talphera (TLPH), and Adial Pharmaceuticals (ADIL). These companies are all part of the "pharmaceutical products" industry.

Galmed Pharmaceuticals vs. Its Competitors

Biofrontera (NASDAQ:BFRI) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Biofrontera presently has a consensus price target of $2.75, suggesting a potential upside of 222.96%. Given Biofrontera's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biofrontera is more favorable than Galmed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biofrontera
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Galmed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galmed Pharmaceuticals has lower revenue, but higher earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$37.32M0.23-$17.76M-$2.26-0.38
Galmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.08

Galmed Pharmaceuticals has a net margin of 0.00% compared to Biofrontera's net margin of -42.34%. Galmed Pharmaceuticals' return on equity of -32.21% beat Biofrontera's return on equity.

Company Net Margins Return on Equity Return on Assets
Biofrontera-42.34% -1,104.09% -82.28%
Galmed Pharmaceuticals N/A -32.21%-28.59%

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Galmed Pharmaceuticals and 3 mentions for Biofrontera. Biofrontera's average media sentiment score of 1.29 beat Galmed Pharmaceuticals' score of 0.98 indicating that Biofrontera is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biofrontera
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Galmed Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biofrontera has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

Summary

Galmed Pharmaceuticals beats Biofrontera on 9 of the 15 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLMD vs. The Competition

MetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.30M$2.51B$5.78B$9.80B
Dividend YieldN/A1.68%3.95%4.02%
P/E Ratio-0.0822.8231.2626.59
Price / SalesN/A729.06454.13168.41
Price / CashN/A177.0937.7359.36
Price / Book0.146.1810.046.68
Net Income-$7.52M$32.94M$3.27B$265.59M
7 Day Performance-6.12%0.99%3.17%3.42%
1 Month Performance-27.75%1.69%4.34%1.09%
1 Year Performance-57.09%11.44%44.12%23.84%

Galmed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLMD
Galmed Pharmaceuticals
1.7579 of 5 stars
$1.38
-0.7%
N/A-60.8%$2.30MN/A-0.0820News Coverage
High Trading Volume
BFRI
Biofrontera
3.1001 of 5 stars
$0.93
flat
$2.75
+195.7%
-21.8%$9.43M$37.32M-0.4170Gap Up
DWTX
Dogwood Therapeutics
1.7928 of 5 stars
$5.30
+7.5%
$10.00
+88.7%
N/A$9.42MN/A-0.285High Trading Volume
PRTG
Portage Biotech
N/A$8.47
-2.4%
N/A+15.2%$9.10MN/A-0.206
SNGX
Soligenix
2.1396 of 5 stars
$4.96
+78.4%
$6.00
+21.0%
-22.9%$9.07M$120K-1.3120High Trading Volume
NLSP
NLS Pharmaceutics
N/A$2.58
+2.8%
N/A+1,183.2%$9.03MN/A0.006Gap Up
RNAZ
TransCode Therapeutics
1.9967 of 5 stars
$10.50
-2.7%
$280.00
+2,566.7%
-99.9%$9MN/A0.009Positive News
CSCI
COSCIENS Biopharma
N/A$2.89
+1.4%
N/AN/A$8.97M$9.59M-0.4820
SNOA
Sonoma Pharmaceuticals
N/A$5.35
flat
N/A+2,007.0%$8.79M$14.91M-2.17180Gap Down
TLPH
Talphera
2.8773 of 5 stars
$0.43
+1.7%
$5.00
+1,056.1%
-44.2%$8.72M$650K-1.0819Gap Down
ADIL
Adial Pharmaceuticals
1.831 of 5 stars
$0.38
-3.5%
$8.00
+2,004.7%
-61.4%$8.60MN/A-0.3620Analyst Revision

Related Companies and Tools


This page (NASDAQ:GLMD) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners